Randomized trial AML HD98B showed that administration of ATRA in addition to intensive chemotherapy improved the outcomes of the patients with genotype of “mutant (mt-) NPM1 without FLT3-ITD” [99]. The gene discussed is NPM1; the disease is acute myeloid leukemia.